The Effect of Metabolic Syndrome on Head and Neck Cancer Incidence Risk: A Population-based Prospective Cohort Study

Huaili Jiang  
Zhongshan Hospital Fudan University  https://orcid.org/0000-0001-8646-8488

Lei Zhou  
Zhongshan Hospital Fudan University

Qiansheng He  
The Seventh Affiliated Hospital Sun Yat-sen University

Kanglun Jiang  
Zhongshan Hospital Fudan University

Xinsheng Huang  (✉ huang.xinsheng@zs-hospital.sh.cn)  
Fudan University  https://orcid.org/0000-0003-3201-4776

Jinqiu Yuan  
The Seventh Affiliated Hospital Sun Yat-sen University

Research

Keywords: metabolic syndrome, metabolic syndrome components, head and neck cancer, C-reactive protein

DOI: https://doi.org/10.21203/rs.3.rs-127272/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

There are limited evidences clarifying the impact of metabolic syndrome (MS) and its components on head and neck cancer (HNC) incidence risk. We explored the correlation between MS, MS components, and the combined effects of MS and C-reactive protein (CRP) and HNC risk.

Methods

This is a prospective analysis of 474,929 participants from the UK Biobank cohort. Cox proportional hazard regression was utilized to assess the hazard ratio (HR) and 95% confidence interval (CI), and to explore the non-linear correlation between an individual MS component and HNC risk.

Results

Individuals with MS (HR, 1.05; 95%CI, 0.90-1.22) had no higher risk of HNC than those without MS and those with more MS components showed no higher HNC risk. Nevertheless, we observed that MS component hyperglycaemia (HR, 1.22; 95%CI, 1.02-1.45) was independently correlated with elevated HNC risk. In a non-linear manner, waist circumference and high-density lipoprotein (HDL) showed a U-shape association with HNC risk. Further linear analysis indicated that male waist circumference, female waist circumference (when ≥ 93.16 cm), male HDL (when ≥ 1.45mmol/L) and blood glucose were positively correlated with HNC risk. Increased CRP (≥ 1.00mg/dL) elevated HNC risk and individuals with MS and CRP ≥ 1.00mg/dL had the highest HNC risk (HR, 1.29; 95%CI, 1.05-1.58).

Conclusions

Although MS are not correlated with elevated HNC risk, high male waist circumference, high female waist circumference (≥ 93.16 cm), high male HDL (≥ 1.45mmol/L) and high blood glucose are independent risk factors of HNC. We also recommended a potential combined effect of MS and CRP in head and neck tumorigenesis.

Introduction

Head and neck cancer (HNC) constituted of 5% of all tumors. Approximately 500,000 individuals are diagnosed each year, of which 350,000 cases die. Sixty percent of patients are already in advanced stage when being diagnosed. Although treatments including surgery, radiotherapy, and chemotherapy have been widely used, the 5-year survival rate of HNC is still only 50%, and the local recurrence rate is up to 50%, and the distant metastasis rate is 25%. Even if the treatment is successful, the patients may cause mental illness due to impaired vocalization, chewing, swallowing, respiratory function, and facial changes induced by surgery or radiotherapy. Studies have shown that among all HNC components, the suicide rate of patients with oral oropharyngeal cancer (53.1/100,000) and laryngeal cancer
(46.8/100,000) second only to lung cancer (81.7/100,000) and stomach cancer (71.7/100,000), ranking third and fourth respectively\(^8\). Therefore, early identification of risk factors is essential to reduce the morbidity and mortality of HNC.

Metabolic syndrome (MS) is a group of metabolic abnormalities, including hypertension, central obesity, elevated triglyceride, low high-density lipoprotein (HDL) cholesterol, and insulin resistance\(^9\). MS or its components are strongly correlated with cancer incidence risk and mortality. It has shown to increase the incidence of liver\(^10,11\), colorectal\(^12-14\), pancreatic\(^15\), endometrial\(^16\) and breast cancer\(^17,18\). MS component diabetes mellitus is also close associated to cancer risk\(^19\) and abdominal obesity is notably correlated with higher risk and mortality of most common cancers\(^20\). The mechanism by which MS may influence cancer development is similar. The possible mechanisms of MS carcinogenesis are as follows: (1) hyperinsulinemia and insulin resistance, (2) chronic subclinical inflammation, (3) abnormal sex hormone metabolism, (4) injury induced by exposure of endocrine disruptors and air pollution, (5) Chronic hyperglycemia and (6) Circadian rhythm disorder\(^21\). To our best knowledge, there is only one investigation showing inverse relations between MS and type 2 diabetes and HNC. However, to date, there have been no studies based on prospective analysis to explore the correlation between MS and HNC risk.

UK Biobank recruited more than 500 thousand participants with an age from 37 to 73 year-old recruited in United Kingdom from year 2006 to 2010. UK Biobank documented beyond 2,000 features, such as anthropometric measurements, sociodemographic assessments, clinical diagnosis and self-reported behavioral outcomes, which provides us with a new chance to assess risk factors of cancer development in a large population-based samples. Based on the UK Biobank dataset, this study tried to clarify the major MS components connected to HNC; to explore possible non-linear correlations between its components and HNC; and to detect the mutual relations amongst MS, C-reactive protein (CRP), and HNC risk.

**Materials And Methods**

**Study design and participants**

Our data application was approved by UK Biobank on August 2019 and the application number was 51671. Detailed information on the research design and data collection methods of UK Biobank cohort have been published\(^23\). We included all UK Biobank participants who reported data on any measure of the MS components. The participants with any cancers being diagnosed before (n = 26868) were excluded (apart from non-melanoma skin cancer with a code of ICD-10 C44). For gestation will increase waist circumference and lead to potential metabolic changes, pregnant women (n = 149) were also excluded. The participants were followed until the date of HNC diagnosis or censoring. HNC was identified if participants were diagnosed as any of the following cancers: laryngeal cancer (ICD-10 C32), nasopharyngeal carcinoma (C11), tonsil cancer (C09), oropharyngeal cancer (C10), hypopharyngeal
carcinoma (C12 and C13), nasal cavity and paranasal sinus cancer (C31) and oral cancer (C00-C06). Finally, 474,929 participants were involved in this study.

**Ethnic statement**

The UK Biobank study was approved by the North West Multi-centre Research Ethics Committee, the England and Wales Patient Information Advisory Group, and the Scottish Community Health Index Advisory Group. All participants provided written informed consent before data collection.

**Data collection**

Participants were invited to fill out a questionnaire during recruitment in their closest assessment center. Sociodemographic characteristics (i.e., age, gender, ethnicity, education, income levels), lifestyle information (i.e., physical activity, tobacco smoking, alcohol drinking), complications (i.e., diabetes mellitus, hypertension) and medicine intake information were collected. The International Physical Activity Questionnaire and the food frequency questionnaire were utilized to evaluate physical activity and diet intake respectively, which has been verified in a previous study. Right arm diastolic and systolic blood pressure (DBP and SBP) was measured twice using an electronic sphygmomanometer and the average value was used. After normal exhalation, a Wessex non-stretchable spring tape measure was utilized to measure the waist circumference (cm) at the level of the umbilicus twice. Plasma concentration of HDL cholesterol, glucose and triglycerides were tested utilizing a Beckman Coulter AU5800 analyzer. The baseline of CRP concentration was quantified utilizing the immuno-turbidimetric method.

**Outcome Assessment**

HNC cases were recognized by establishing links with the Health and Social Care Information Centre (located in England and Wales) and the Cancer and Death Registry of the National Health Service Central Register (located in Scotland). For more details about the linking process, please visit https://biobank.ndph.ox.ac.uk/showcase/refer.cgi?id=115558. The person-years were calculated recruitment date to any dates of death, the first HNC, or the end of follow-up (October 30, 2015).

**Definition for MS and MS components**

We used the definition criteria of MS and its components developed by the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI). Individuals with body mass index (BMI) greater than 30 kg/m², or the waist circumference more than the values of cut points that are population- and country-specific definitions was diagnosed as central obesity. Dyslipidaemia for triglycerides (TG) was defined as plasma TG concentration ≥ 1.7 mmol/L (150 mg/dL) or currently on medications for hypertriglyceridemia. HDL cholesterol < 1.0 mmol/L (40 mg/dL) for males and < 1.30 mmol/L (50 mg/dL) for females or specific treatment for previously detected decreased HDL cholesterol was defined as dyslipidaemia for HDL. Hypertension was diagnosed if blood pressure was over 130/85 mmHg, or already receiving antihypertensive treatment. Hyperglycaemia was described as
previously diagnosed type 2 diabetes or fasting plasma glucose $\geq 5.56$ mmol/L (100 mg/dL). Participants with 3 or more of 5 risk factors will be diagnosed with metabolic syndrome$^9$.

**Data Analysis**

Cox regression models were utilized to calculate the hazard ratio (HR) and 95% confidence interval (CI) for the correlation of MS and its components with HNC incidence risk. To compare the effect among MS components, we analyzed them as continuous variables to estimate HRs per standard deviation (SD) increase. In addition, we utilized restricted cubic splines for each MS component to explore their potential non-linear correlation with HNC risk. Further, to explore the combined effect between CRP and MS on the influence of HNC risk, we defined 4 risk levels according to MS or CRP levels with a cut-off point of 1.00 mg/dL. And the HRs for HNC risk were calculated when comparing to the No MS plus CRP < 1.00 mg/dL group.

The unadjusted model (model 1) was first conducted. Then we adjusted age and gender in model 2. In model 3, ethnic, education level, index of multiple deprivations, tobacco smoking status, alcohol drinking status, physical activity and portions of fruit and vegetable intake were further adjusted.

$P < 0.05$ with two-tailed was considered as statistical significance. R software (version 3.6.1) was utilized for all statistical analysis.

**Results**

Among all participants, nearly one-third of them were diagnosed as MS ($n = 140346, 29.6\%$). As expected, the participants with MS have higher waist circumference, BMI, blood pressure, the plasma concentration of fasting glucose, TG, and CRP, but lower concentration of HDL cholesterol. MS participants appeared to be older, to have a higher multiple deprivation index, and to have less physical activity. Table 1 showed the baseline characteristics.
Table 1
Baseline characteristics of participants according to MS in the UK biobank cohort.

| Metabolic syndrome (N) | No (n = 334583) | Yes (n = 140346) |
|------------------------|-----------------|------------------|
| Average follow-up years, Mean (SD) | 6.58 (1.23) | 6.49 (1.30) |
| Age at participation, Mean (SD) | 55.5 (8.15) | 58.3 (7.64) |
| BMI, Mean (SD), kg/m² | 25.9 (3.86) | 31.0 (4.90) |
| Waist circumference, Mean (SD), cm | 85.8 (11.3) | 101 (12.1) |
| HDL cholesterol, Mean (SD), mmol/L | 1.55 (0.366) | 1.22 (0.303) |
| Triglycerides, Mean (SD), mmol/L | 1.44 (0.777) | 2.42 (1.19) |
| Fasting glucose, Mean (SD), mmol/L | 4.88 (0.671) | 5.63 (1.87) |
| SBP, Mean (SD), mm Hg | 137 (19.7) | 146 (17.9) |
| DBP, Mean (SD), mm Hg | 80.9 (10.6) | 85.4 (10.3) |
| Primary site of cancer, N | | |
| Larynx | 61 | 42 |
| Tonsil | 92 | 42 |
| Oral cavity | 181 | 111 |
| Nasal cavity and sinuses | 16 | 6 |
| Oropharynx | 14 | 7 |
| Hypopharynx | 20 | 4 |
| Others | 111 | 99 |
| Gender, N (%) | | |
| Female | 188906 (56.5%) | 66956 (47.7%) |
| Male | 145677 (43.5%) | 73390 (52.3%) |
| Education level, N (%) | | |
| College or University degree | 117845 (35.2%) | 35265 (25.1%) |
| Other | 162865 (48.7%) | 70220 (50.0%) |
| unknown/missing | 53873 (16.1%) | 34861 (24.8%) |
| Ethnicity, N (%) | | |
| Non-White | 315381 (94.3%) | 131082 (93.4%) |
| Metabolic syndrome (N)                | No (n = 334583) | Yes (n = 140346) |
|--------------------------------------|-----------------|------------------|
| white                                | 17645 (5.3%)    | 8492 (6.1%)      |
| unknown/missing                      | 1557 (0.5%)     | 772 (0.6%)       |
| Index of multiple deprivation quintile, N (%) |
| 1th                                  | 61047 (18.2%)   | 20643 (14.7%)    |
| 2th                                  | 59990 (17.9%)   | 21823 (15.5%)    |
| 3th                                  | 58520 (17.5%)   | 23158 (16.5%)    |
| 4th                                  | 56301 (16.8%)   | 25571 (18.2%)    |
| 5th                                  | 52601 (15.7%)   | 29330 (20.9%)    |
| missing                              | 46124 (13.8%)   | 19821 (14.1%)    |
| Smoking status, N (%)                |
| Current                              | 34587 (10.3%)   | 15915 (11.3%)    |
| Previous                             | 107678 (32.2%)  | 54704 (39.0%)    |
| Never                                | 190793 (57.0%)  | 68809 (49.0%)    |
| unknown/missing                      | 1525 (0.5%)     | 918 (0.7%)       |
| Alcohol consumption, N (%)           |
| Daily or almost daily                | 72332 (21.6%)   | 23976 (17.1%)    |
| 1–4 times a week                     | 169384 (50.6%)  | 62723 (44.7%)    |
| One to three times a month           | 35496 (10.6%)   | 17363 (12.4%)    |
| Special occasions only or never      | 56642 (16.9%)   | 35901 (25.6%)    |
| unknown/missing                      | 729 (0.2%)      | 383 (0.3%)       |
| Physical activity, N (%)             |
| Low                                  | 44878 (13.4%)   | 26981 (19.2%)    |
| Moderate                             | 109466 (32.7%)  | 45595 (32.5%)    |
| High                                 | 117170 (35.0%)  | 37074 (26.4%)    |
| unknown/missing                      | 63069 (18.9%)   | 30696 (21.9%)    |
| Portions of fruit and vegetable intake, Mean (SD) |
| no                                   | 4.66 (3.11)     | 4.52 (3.16)      |
| NSAIDS, N (%)                        |
| no                                   | 209520 (62.6%)  | 67714 (48.2%)    |
During an average follow-up of 6.5 years, we recorded 806 HNC cases. Overall, individuals with MS had no significant effect on risk of HNC compared to those without MS (HR, 1.05; 95%CI, 0.90–1.22). More MS components led to higher risk of HNC (3 components: HR, 1.04; 95%CI, 0.88–1.24; 4 components: HR, 1.00; 95%CI, 0.80–1.26; 5 components: HR, 1.30; 95%CI, 0.92–1.84), but no statistical differences were detected. Analysis of MS components reveals that individuals with dyslipidemia for TG (HR, 1.31; 95%CI, 1.31–1.51), hypertension (HR, 1.23; 95%CI, 1.02–1.48) and hyperglycemia (HR, 1.35; 95%CI, 1.14–1.61) had higher hazard for HNC (model 1). After being adjusted by age and gender (model 2), ethnic, education, Index of multiple deprivations, alcohol drinking status, smoking status, fruit and vegetable intake, physical activity, NSAIDS use and CRP (model 3), the association remained noticeably for hyperglycemia (HR, 1.22; 95%CI, 1.02–1.45). See details in Table 2.
Table 2
Risk of head and neck cancer according to MS and its components

|                               | No of cases/Person-years | Model 1 |       | Model 2 |       | Model 3 |       |
|-------------------------------|--------------------------|---------|-------|---------|-------|---------|-------|
|                               |                          | HR (95%CI) | P     | HR (95%CI) | P     | HR (95%CI) | P     |
| **Presence of MS**            |                          |          |       |          |       |          |       |
| No                            | 495/2201184              | Reference | Reference | Reference | Reference | Reference | Reference |
| Yes                           | 311/910374               | 1.27[1.10, 1.47] | 0.001 | 1.18[1.02, 1.36] | 0.023 | 1.05[0.90, 1.22] | 0.560 |
| **No. of MS components**      |                          |          |       |          |       |          |       |
| 0–2                           | 483/2167132              | Reference | Reference | Reference | Reference | Reference | Reference |
| 3                             | 191/582520               | 1.25[1.06, 1.48] | 0.009 | 1.14[0.96, 1.35] | 0.126 | 1.04[0.88, 1.24] | 0.645 |
| 4                             | 95/283291                | 1.26[1.01, 1.57] | 0.043 | 1.16[0.93, 1.45] | 0.187 | 1.00[0.80, 1.26] | 0.978 |
| 5                             | 37/78614                 | 1.70[1.22, 2.38] | 0.002 | 1.58[1.13, 2.21] | 0.008 | 1.30[0.92, 1.84] | 0.132 |
| **Center obesity**            |                          |          |       |          |       |          |       |
| No                            | 500/2065978              | Reference | Reference | Reference | Reference | Reference | Reference |
| Yes                           | 304/1036668              | 1.10[0.95, 1.26] | 0.211 | 1.19[1.04, 1.38] | 0.015 | 1.04[0.90, 1.21] | 0.592 |
| **Dyslipidaemia for TG**      |                          |          |       |          |       |          |       |
| No                            | 141/845849               | Reference | Reference | Reference | Reference | Reference | Reference |
| Yes                           | 665/2262915              | 1.31[1.13, 1.51] | < 0.001 | 1.06[0.91, 1.23] | 0.461 | 0.95[0.81, 1.10] | 0.472 |
| **Dyslipidaemia for HDL**     |                          |          |       |          |       |          |       |
| No                            | 301/1501095              | Reference | Reference | Reference | Reference | Reference | Reference |

model 1: unadjusted
model 2: Age and gender-stratified model
model 3: additionally adjusted for education, ethnic, Index of multiple deprivation, alcohol consumption, smoking status, physical activity, fruit and vegetable intake, NASIDS use and CRP;
| No of cases/Person-years | Model 1 | Model 2 | Model 3 |
|--------------------------|---------|---------|---------|
|                          | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P |
| **Yes**                  | 464/1438442 | 1.16[0.98, 1.39] | 0.091 | 1.17[0.98, 1.39] | 0.087 | 1.01[0.84, 1.22] | 0.877 |
| **Hypertension**         |         |         |         |         |         |         |
| No                      | 528/2095502 | Reference | Reference | Reference |
| Yes                     | 160/568287 | 1.23[1.02, 1.48] | 0.027 | 1.02[0.84, 1.22] | 0.874 | 1.00[0.82, 1.20] | 0.973 |
| **Hyperglycaemia**       |         |         |         |         |         |         |
| No                      | 529/2226708 | Reference | Reference | Reference |
| Yes                     | 174/459089 | 1.35[1.14, 1.61] | 0.001 | 1.26[1.06, 1.5] | 0.009 | 1.22[1.02, 1.45] | 0.028 |

model 1: unadjusted
model 2: Age and gender-stratified model
model 3: additionally adjusted for education, ethnic, Index of multiple deprivation, alcohol consumption, smoking status, physical activity, fruit and vegetable intake, NASIDS use and CRP;

When assessing the non-linear effect between individual MS components and HNC incidence risk, we observed a significant U-shape association for waist circumference (Fig. 1A, p-non-linear = 0.004) and HDL (Fig. 1E, p-non-linear = 0.005). Further, we analyzed their association for each gender, which showed that there was no non-linear relation between male waist circumference (Fig. 1B, p-non-linear = 0.394), female HDL (Fig. 1G, p-non-linear = 0.879) and HNC risk. However, a U-shape association between female waist circumference (Fig. 1C, p-non-linear = 0.031), male HDL (Fig. 1F, p-non-linear = 0.005) and HNC risk was observed. No relation was found for TG (Fig. 1D, p-non-linear = 0.098), SBP (Fig. 1H, p-non-linear = 0.849), DBP (Fig. 1I, p-non-linear = 0.258) and blood glucose (Fig. 1J, p-non-linear = 0.075). Based on this results, we divided the female waist circumference and male HDL into two sections with 93.16 cm and 1.45 mmol/L respectively according to the lowest point of U-shape curves to further perform linear analysis.

The linear effect between HNC risk and each MS component was showed in Table 3. Higher male waist circumference was correlated with elevated HNC risk (HR, 1.10; 95%CI, 1.02−1.20). Low female waist circumference (< 93.16 cm) showed no influence on the risk of HNC (HR, 0.92; 95%CI, 0.78−1.08); however, high female waist circumference (≥ 93.16 cm) was positively correlated with HNC risk (HR, 1.47; 95%CI, 1.15−1.89). Interestingly, higher male HDL increased HNC risk (HR, 1.19; 95%CI, 1.04, 1.36) when the concentration was more than 1.45 mmol/L. Male participants had no significant increased risk of HNC (HR, 0.94; 95%CI, 0.85−1.04) when HDL was less than 1.45 mmol/L and there was no correlation
between female HDL with HNC risk (HR, 1.08; 95%CI, 0.92–1.27). Higher blood glucose was correlated with higher HNC risk (HR, 1.06; 95%CI, 1.00-1.12). No relation was found for TG (HR, 0.99; 95%CI, 0.93–1.07), SBP (HR, 1.03; 95%CI, 0.96–1.10) and DBP (HR, 1.00; 95%CI, 0.93–1.08).

Table 3
Risk of head and neck cancer in the UK biobank cohort in relation to MS components

| MS components          | Model 1        | Model 2        | Model 3        |
|------------------------|----------------|----------------|----------------|
|                        | HR (95% CI)    | P              | HR (95% CI)    | P              | HR (95% CI)    | P              |
| Waist circumference (male)| 1.19[1.10, 1.28] | < 0.001        | 1.19[1.10, 1.28] | < 0.001        | 1.10[1.02,1.20] | 0.019          |
| <93.16 cm              | 0.94[0.80, 1.11] | 0.469          | 0.94[0.80, 1.11] | 0.471          | 0.92[0.78,1.08] | 0.311          |
| ≥93.16 cm              | 1.42[1.11, 1.80] | 0.005          | 1.41[1.11, 1.80] | 0.005          | 1.47[1.15,1.89] | 0.003          |
| Triglycerides (mmol/L) | 1.12[1.05, 1.20] | < 0.001        | 1.03[0.97, 1.11] | 0.339          | 0.97[0.91,1.04] | 0.407          |
| HDL cholesterol (male) |                |                |                |                |                |                |
| <1.45 mmol/L           | 0.88[0.80, 0.98] | 0.014          | 0.88[0.80, 0.98] | 0.014          | 0.94[0.85,1.04] | 0.208          |
| ≥1.45 mmol/L           | 1.23[1.08, 1.40] | 0.002          | 1.23[1.08, 1.41] | 0.001          | 1.19[1.04,1.36] | 0.009          |
| HDL cholesterol (female)|                |                |                |                |                |                |
| <1.45 mmol/L           | 1.02[0.87, 1.18] | 0.830          | 1.02[0.88, 1.18] | 0.821          | 1.08[0.92,1.27] | 0.344          |
| Diastolic blood pressure (mmHg) | 1.07[1.00, 1.05] | 0.043          | 0.99[0.92, 1.06] | 0.716          | 0.99[0.93,1.07] | 0.848          |
| Systolic blood pressure (mmHg) | 1.09[1.01, 1.17] | 0.018          | 1.03[0.96, 1.11] | 0.415          | 1.03[0.96,1.10] | 0.451          |
| Blood glucose (mmol/L) | 1.09[1.03, 1.15] | 0.002          | 1.07[1.01, 1.13] | 0.018          | 1.06[1.00,1.12] | 0.044          |

model 1: unadjusted
model 2: Age and gender-stratified model
model 3: additionally adjusted for education, ethnic, Index of multiple deprivation, alcohol consumption, smoking status, physical activity, fruit and vegetable intake, NASIDS use and CRP;

We further explore the relation between HNC incidence risk and CRP, the combined effect of CRP and MS as well. Elevated CRP more than 1.00 mg/dL elevated the risk for HNC (HR, 1.21; 95%CI, 1.02–1.43)
compared to it lower than 1.00 mg/dL (model 3). After evaluating the combined effect of CRP and MS, it was found that both no MS plus elevated CRP (HR, 1.22; 95%CI, 1.02–1.47) and MS plus elevated CRP (HR, 1.29; 95%CI, 1.05–1.58) participants had increased HNC risk compared to those without MS and CRP < 1.00 mg/dL. See details in Table 4.

Table 4
Hazard ratios (HR) with 95% confidence intervals (CI) for head and neck cancer by CRP and joint effect of MS and CRP

| CRP                  | No. of cases / Person-years | Model 1                | Model 2                | Model 3                |
|----------------------|----------------------------|------------------------|------------------------|------------------------|
|                      |                            | HR (95% CI)            | P                      | HR (95% CI)            | P                      |
| CRP                  |                            |                        |                        |                        |
| < 1.00 mg/dL         | 223/1155432                | Reference              | Reference              | Reference              |
| ≥ 1.00 mg/dL         | 531/1750092                | 1.39 [1.18, 1.62]      | < 0.001                | 1.44 [1.23, 1.68]      | < 0.001                |
| **Joint effect of**  |                            |                        |                        |                        |
| **MS and CRP**       |                            |                        |                        |                        |
| No MS/CRP < 1.00 mg/dL | 181/1027524            | Reference              | Reference              | Reference              |
| No MS/CRP ≥ 1.00 mg/dL | 327/1153876            | 1.42 [1.19, 1.72]      | < 0.001                | 1.45 [1.21, 1.73]      | < 0.001                |
| MS/CRP < 1.00 mg/dL  | 42/127908                 | 1.50 [1.07, 2.10]      | 0.018                  | 1.30 [0.93, 1.82]      | 0.126                  |
| MS/CRP ≥ 1.00 mg/dL  | 204/596216                | 1.58 [1.29, 1.93]      | < 0.001                | 1.61 [1.31, 1.96]      | < 0.001                |

**model 1**: Unadjusted

**model 2**: Age and gender-stratified model

**model 3**: additionally adjusted for education, ethnic, Index of multiple deprivation, alcohol consumption, smoking status, physical activity, fruit and vegetable intake, and NASIDS use;

**Discussion**

This is a prospective cohort study involving 474,929 participants and 806 HNC cases. We observed that individuals with MS had no elevated incidence risk of HNC and the risk did not elevate with the amount of MS components. Only hyperglycaemia was independently correlated with HNC risk among all MS components. Linear analysis revealed that male waist circumference, female waist circumference (≥ 93.16 cm), male HDL (≥ 1.45 mmol/L) and blood glucose for each gender were positively correlated with HNC risk. CRP was positively correlated with an elevated incidence risk of HNC, and the risk was elevated in participants with MS, demonstrating MS and CRP had joint effect on the risk of HNC. Our study
comprehensively explored the correlation between MS and HNC risk in the general population and indicated an inflammatory mechanism for HNC development.

To date, there was only one study that exploring the effect of MS on the risk of HNC\textsuperscript{22}. Stott-Miller M et al. suggested a moderate inverse relation between MS and HNC. However, in our study, we observed no association between MS and HNC risk after adjusting several confounders. It is worth noting that Stott-Miller M’s study is a retrospective study, but our results is based on a prospective cohort study which have higher evidence level. Inadequate control of key confounding variables, including obesity, smoking time and smoking intensity in Stott-Miller M’s study may also lead to the observed reverse association.

Additionally, some researches have assessed the influence of MS on HNC component risk. Zucchetto et al. found no overall association between MS and nasopharyngeal carcinoma, but MS increased the risk of differentiated nasopharyngeal carcinoma\textsuperscript{27}. However, a study conducted in South Korea by Sang-Yeon Kim claimed that MS was an independent risk factor for laryngeal cancer incidence\textsuperscript{28}. Therefore, further analyses concerning the association between MS and HNC subgroups are meaningful in future studies.

In the present study, we observed that one MS component hyperglycaemia was independently associated with increased HNC risk. Hyperglycaemia is considered to be a critical factor in the pathophysiology of MS. Hyperglycaemia, Hyperinsulinemia and insulin resistance are increasing proliferation, angiogenesis, and the destruction of DNA molecules by oxygen-active forms caused by excess glucose, cell migration and apoptosis\textsuperscript{29–31}. Previous studies suggested that MS elevated the incidence risk of cancer through the change of insulin receptors and activation of growth and transcription factors\textsuperscript{32, 33}. Several studies have evaluated the influence of diabetes on HNC risk\textsuperscript{22, 34–36}. Stott-Miller M\textsuperscript{22} suggested that type II diabetes slightly decreased HNC risk. However, the other three studies revealed that diabetes increased HNC risk. Our study observed that blood glucose concentration was an independent risk factor for HNC development. Overweight/obesity is strongly correlated with glucose intolerance and type II diabetes\textsuperscript{37, 38}; however, our study observed that central obesity was not an independent risk factor for HNC. Further analysis suggested that waist circumference was significantly correlated with HNC risk in a U-shape manner and higher female waist circumference increased risk when it was more than 93.16 cm, which was consistent with the previous study that suggested moderate-intensity physical activity (equal to short-distance running) may be beneficial for reducing laryngeal cancer risk\textsuperscript{39}. Interestingly, some studies have showed that high level of HDL is protective against cancer; however, we found that high HDL level also increase the risk of HNC in men. HDL levels are higher in patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer. In this part of patients, high HDL levels seem to increase sensitivity to EGFR-tyrosine kinase inhibitors\textsuperscript{40}. As well known, more than 70% of HNC have EGFR gene mutations, which may explain why high HDL increase risk of HNC. The concentration of triglycerides, diastolic and systolic blood pressure had no independent influence on HNC risk.

Disorders of the inflammatory condition induced by MS may play an essential role the tumorigenesis. To date, no studies were available in exploring the influence of CRP on HNC risk. In the present study, our
results indicated that CRP, a sensitive biomarker of inflammation in vivo, was independently correlated with an increased HNC incidence risk. Additionally, the HNC risk induced by MS plus CRP was further increased when compared with MS alone or elevated CRP alone. MS individuals had higher blood CRP, regardless of the diverse definition for MS and its components in different studies41–43. This suggested that HNC development in MS individuals may attribute to the inflammatory system disruption. Therefore, it is critical to analyze the combined effects of MS and CRP during early intervention. Further researches are needed to verify these findings.

The primary benefit of this study is that the data are based on a prospective cohort study from the UK biobank, with a verified follow-up time (average 6.5 years) and detailed measurement results. This allows potential confounding factors to adjust the correlation of interest simultaneously. In addition, we investigate the linear and non-linear relationship between all MS components and HNC risk, which has rarely been published in previous studies. Besides, we evaluated the interaction of MS and CRP with HNC, which may provide a pathological basis for MS tumorigenesis.

This study still has some limitations. First, as an observational study, although we have used complementary analytical methods to assess its epidemiological relationship steadily, we cannot assess the exact causal relationship between MS and HNC development. Second, because the MS component has only been measured once, it is impossible to assess these risk factors' impact over time. Finally, due to the absence of histological information, it was limited to analyze the effects of MS on the HNC subtype.

In conclusion, this study suggested no correlation between MS and HNC risk. However, high male waist circumference, high female waist circumference (≥ 93.16 cm), high male HDL (≥ 1.45 mmol/L) and high blood glucose are independently elevated the risk of HNC. We also indicated a combined effect of MS and CRP in HNC tumorigenesis, which may bring us new perception to study the pathological changes of HNC development.

Declarations

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Authors' Contributions:

Conception and design: Huaili Jiang, Jinqiu Yuan and Xinsheng Huang.

Development of methodology: Huaili Jiang and Qiangsheng He.

Acquisition of data: Huaili Jiang, Lei Zhou.
Data analysis and explanation (e.g., computational analysis, statistical analysis, biostatistics): Huaili Jiang and Qiangsheng He.

Figure and table preparing: Huaili Jiang and Kanglun Jiang

Writing and revision of the manuscript: Huaili Jiang and Kanglun Jiang.

Study supervision: Jinqiu Yuan and Xinsheng Huang.

Acknowledgments

This study was supported by Youth Fund of Zhongshan Hopsital of Fudan University (The function and mechanism of TREM-2-mediated osteoclast maturation in human acquired choleasteatoma-indued bone destruction. Foundation number: 2019ZSQN32) and the Shanghai Science and Technology Committee foundation (Effect of artificial ossicular and estimated connection on tympanic membrane fatigue life in ossicular chain reconstruction. Foundation number: 17411962220).

Funding

No

Conflicts of Interest Statement

There are no potential conflicts of interest to declare.

References

1. Reuter CW, Morgan MA, Eckardt A. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer. 2007;96:408-416.

2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.

3. Guo W, Song H. Development of Gene Therapeutics for Head and Neck Cancer in China: From Bench to Bedside. Hum Gene Ther. 2018;29:180-187.

4. Kang H, Kiess A, Chung CH. Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol. 2015;12:11-26.

5. Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc. 2016;91:386-396.

6. Boussios S, Seraj E, Zarkavelis G, et al. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. Crit Rev Oncol Hematol. 2016;108:164-174.

7. Peng PJ, Lv BJ, Wang ZH, et al. Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of
platinum-containing regimens. *Ther Adv Med Oncol*. 2017;9:68-74.

8. Stephanie Misono, Noel S Weiss, Jesse R Fann, Mary Redman, Bevan Yueh. Incidence of suicide in persons with cancer. *J Clin Oncol*. 2008 Oct 10;26(29):4731-8.

9. K G M M Alberti, Robert H Eckel, Scott M Grundy, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*. 2009 Oct 20; 120(16):1640-5.

10. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. *Cancer*. 2009;115:5651-5661.

11. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. *Hepatology*. 2011;54:463-471.

12. Chiu HM, Lin JT, Shun CT, et al. Association of metabolic syndrome with proximal and synchronous colorectal neoplasm. *Clin Gastroenterol Hepatol*. 2007;5:221-229; quiz 141.

13. Pais R, Silaghi H, Silaghi AC, Rusu ML, Dumitrascu DL. Metabolic syndrome and risk of subsequent colorectal cancer. *World J Gastroenterol*. 2009;15:5141-5148.

14. Aleksandrova K, Boeing H, Jenab M, et al. Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. *Cancer Prev Res (Phila)*. 2011;4:1873-1883.

15. Johansen D, Stocks T, Jonsson H, et al. Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the Metabolic Syndrome and Cancer Project. *Cancer Epidemiol Biomarkers Prev*. 2010;19:2307-2317.

16. Rosato V, Zucchetto A, Bosetti C, et al. Metabolic syndrome and endometrial cancer risk. *Ann Oncol*. 2011;22:884-889.

17. Kabat GC, Kim M, Chlebowski RT, et al. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. *Cancer Epidemiol Biomarkers Prev*. 2009;18:2046-2053.

18. Xue F, Michels KB. Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. *Am J Clin Nutr*. 2007;86:s823-835.

19. Jee SH, Ohr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. *JAMA*. 2005;293:194-202.

20. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. *Nat Rev Cancer*. 2004;4:579-591.

21. Bellastella G, Scappaticcio L, Esposito K, Giugliano D, Maiorino MI. Metabolic syndrome and cancer: "The common soil hypothesis". *Diabetes Res Clin Pract*. 2018;143:389-397.

22. Stott-Miller M, Chen C, Schwartz SM. Type II diabetes and metabolic syndrome in relation to head and neck squamous cell carcinoma risk: a SEER-Medicare database study. *Cancer Epidemiol*. 2018;40:220-228.
2013;37:428-433.
23. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS medicine*. 2015;12:e1001779.
24. Cassidy S, Chau JY, Catt M, Bauman A, Trenell MI. Cross-sectional study of diet, physical activity, television viewing and sleep duration in 233,110 adults from the UK Biobank; the behavioural phenotype of cardiovascular disease and type 2 diabetes. *BMJ open*. 2016;6:e010038.
25. Caulfield M, Munroe P, Pembroke J, et al. Genome-wide mapping of human loci for essential hypertension. *Lancet*. 2003;361:2118-2123.
26. Sabatine MS, Morrow DA, Jablonski KA, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. *Circulation*. 2007;115:1528-1536.
27. Zucchetto A, Taborelli M, Bosetti C, et al. Metabolic disorders and the risk of nasopharyngeal carcinoma: a case-control study in Italy. *Eur J Cancer Prev*. 2018;27:180-183.
28. Kim SY, Han KD, Joo YH. Metabolic Syndrome and Incidence of Laryngeal Cancer: A Nationwide Cohort Study. *Sci Rep*. 2019;9:667.
29. Berstein LM. Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond. *Future Oncol*. 2010;6:1313-1323.
30. Chia PP, Fan SH, Say YH. Screening of Peroxisome Proliferator-Activated Receptors (PPARs) alpha, gamma and alpha Gene Polymorphisms for Obesity and Metabolic Syndrome Association in the Multi-Ethnic Malaysian Population. *Ethn Dis*. 2015;25:383-390.
31. Yunusova NV, Spirina LV, Frolova AE, Afanas'ev SG, Kolegova ES, Kondakova IV. Association of IGFBP-6 Expression with Metabolic Syndrome and Adiponectin and IGF-IR Receptor Levels in Colorectal Cancer. *Asian Pac J Cancer Prev*. 2016;17:3963-3969.
32. Wang Y, Gao C, Zhang Y, et al. Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways. *Gynecol Oncol*. 2016;143:168-178.
33. Gao J, Tian J, Lv Y, et al. Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. *Cancer Sci*. 2009;100:389-395.
34. Stott-Miller M, Chen C, Chuang SC, et al. History of diabetes and risk of head and neck cancer: a pooled analysis from the international head and neck cancer epidemiology consortium. *Cancer Epidemiol Biomarkers Prev*. 2012;21:294-304.
35. Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. *J Natl Cancer Inst*. 1997;89:1360-1365.
36. Suba Z. Gender-related hormonal risk factors for oral cancer. *Pathol Oncol Res*. 2007;13:195-202.
37. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature*. 2006;444:840-846.
38. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. *Lancet.* 2005;365:1333-1346.

39. Nocini R, Sanchis-Gomar F, Lippi G. Physical activity and laryngeal cancer. *Ann Transl Med.* 2019;7:791.

40. Yang Lv, Li-Yun Miao, Qiu-Fang Chen, et al. Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma. *Onco Targets Ther.* 2016 Jan 22;9:461-8.

41. Mirhafez SR, Ebrahimi M, Saberi Karimian M, et al. Serum high-sensitivity C-reactive protein as a biomarker in patients with metabolic syndrome: evidence-based study with 7284 subjects. *Eur J Clin Nutr.* 2016;70:1298-1304.

42. Ohkuma T, Fujii H, Iwase M, et al. U-shaped association of sleep duration with metabolic syndrome and insulin resistance in patients with type 2 diabetes: the Fukuoka Diabetes Registry. *Metabolism.* 2014;63:484-491.

43. Stroescu RF, Marginean O, Bizerea T, Gafencu M, Voicu A, Doros G. Adiponectin, leptin and high sensitivity C-reactive protein values in obese children - important markers for metabolic syndrome? *J Pediatr Endocrinol Metab.* 2019;32:27-31.